



Figure 1

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*




3
 IC_{50} values
 D_{2L} (human) < 500 nM
 $D_{4.4}$ (human) > 1 μ M
 $5HT_{1A}$ (human) < 500 nM
 $5HT_{2A}$ (human) < 100 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 100 nM
 α_{1A} (rat) < 100 nM
 α_{1D} (human) < 100 nM
 α_{2A} (human) < 1 μ M



4
 IC_{50} values
 D_{2L} (human) < 500 nM
 $5HT_{2A}$ (human) < 100 nM
 $5HT_{2B}$ (human) < 10 nM
 $5HT_{2C}$ (human) < 500 nM

Figure 2

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



5


IC_{50} values

D_{2L} (human) < 5 μ M

5HT_{2A} (human) < 10 nM

5HT_{2B} (human) < 10 nM

5HT_{2C} (human) < 10 nM



6

IC_{50} values

D_{2L} (human) < 5 μ M


5HT_{2A} (human) < 10 nM

5HT_{2B} (human) < 100 nM

5HT_{2C} (human) < 10 nM

Figure 3


*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



7

IC_{50} values

D_{2L} (human) > 1 μ M
 D_3 (human) < 1 μ M
 $5HT_1$ (rat) > 1 μ M
 $5HT_{1A}$ (human) < 500 nM
 $5HT_2$ (rat) < 100 nM
 $5HT_{2A}$ (human) < 10 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 100 nM




8

IC_{50} values

D_{2L} (human) < 1 μ M
 D_3 (human) < 1 μ M
 $5HT_1$ (rat) > 1 μ M
 $5HT_{1A}$ (human) < 1 μ M
 $5HT_2$ (rat) < 100 nM
 $5HT_{2A}$ (human) < 10 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 10 nM

Figure 4

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



9

IC_{50} values

D_{2L} (human) < 1 μ M

D_3 (human) < 500 nM

$D_{4.4}$ (human) > 1 μ M

5HT_{1A} (human) < 500 nM

5HT_{2A} (human) < 500 nM

5HT_{2B} (human) < 100 nM


5HT_{2C} (human) < 500 nM

5HT₆ (human) > 1 μ M

α_{1A} (rat) < 1 μ M

α_{1D} (human) > 1 μ M

α_{2A} (human) > 1 μ M



11

IC_{50} values

D_{2L} (human) < 1 μ M

D_{2S} (human) < 1 μ M

D_3 (human) < 1 μ M

$D_{4.4}$ (human) > 1 μ M

5HT₂ (rat) > 1 μ M


5HT₃ (human) > 1 μ M

5HT₆ (human) > 1 μ M

5HT₇ (human) < 1 μ M

Figure 5

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



13

IC_{50} values

D_{2L} (human) < 500 nM

$5HT_{2A}$ (human) < 100 nM


$5HT_{2B}$ (human) < 100 nM

$5HT_{2C}$ (human) < 500 nM

α_{1A} (rat) > 1 μ M

α_{1D} (human) < 500 nM

α_{2A} (human) < 1 μ M



14

IC_{50} values

D_{2L} (human) < 500 nM

$5HT_{2A}$ (human) < 500 nM

$5HT_{2B}$ (human) < 100 nM

$5HT_{2C}$ (human) < 500 nM


α_{1A} (rat) < 100 nM

α_{1D} (human) < 100 nM

α_{2A} (human) < 1 μ M

Figure 6

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



15

IC_{50} values

NE Transporter (human) <500 nM


D_{2L} (human) <500 nM

D₃ (human) <500 nM

DA Transporter (human) <100 nM

5-HT₇ (human) <500 nM

5-HT Transporter (human) >1 μ M



16

IC_{50} values

alpha 1 (rat) <1 μ M

alpha 2 (rat) <1 μ M

D_{2L} (human) <1 μ M

D_{2S} (human) >1 μ M

D₃ (human) <1 μ M

D_{4.4} (human) >1 μ M

5-HT₇ (human) <1 μ M

5-HT_{2A} (human) <1 μ M